Australia is closely watching the arrival of retatrutide, a novel dual GIP and GLP-1 receptor medication , representing a significant advance in addressing excess weight. Early study data have demonstrated https://susanxmkl565448.ssnblog.com/42261267/new-treatment-in-australia-a-new-hope-for-obesity-management